Generic News: Breaking Generic News, Comments and Articles. - Page: 5

Teva: An Ideal Long-Term Pharma Stock

ByEmerging Equities:A study released by the IMS Institute for Health Informatics finds that per capita spending on medicines declined by $33 in 2012. On one side, the report raises the question of whether this is good or bad. Is it due to better utilization of healthcare resources, or does it signify "under-treatment and an imbalance between prevention and care"? On the other side, it tries to und...

Actavis and Warner Chilcott leap on merger talks; possible bid for Adcock Ingram

US generics major Actavis NYSE: ACT) confirmed on Friday (May 10) that it has entered into early stage discussions with Ireland-based Warner Chilcott (Nasdaq: WCRX) regarding a potential combination of the two companies. Actavis further stated that n...

US FDA to allow generic copies of Endo's Opana

Endo Health Solutions (Nasdaq: ENDP) announced Friday (May 10) that the US Food and Drug Administration has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals, regarding the potential approval of additional non-abuse deterrent fo...

Coland, ScinoPharm To Partner For Cancer Drugs In Mainland China

Hong Kong's Coland Holdings and ScinoPharm Taiwan plan to collaborate with a yet-to-be-chosen third company in developing generic cancer drugs on the China mainland.

The Week in Review: Sagent Buys Out China JV Partner for $25 Million

Sagent Pharma, a US generic injectible drugmaker, will pay $25 million to acquire its partner’s 50% interest in a China manufacturing JV; ScinoPharm Taiwan and Coland Holdings formed a partnership to bring generic oncology drugs to mainland Chi...

China Biotech In Review: Sagent Buys Out China JV Partner For $25 Million

By ChinaBio Today: Deals and Financings Sagent Pharmaceuticals (NSDQ: SGNT), a Chicago-area maker of generic injectible drugs, will acquire its partner's 50% interest in a China JV for $25 million (see story). Chengdu Kanghong Pharmaceuticals owned the other half of the JV, which was established in 2006 to build an FDA/GMP compliant manufacturing facility. Sagent apparently expects to use the...

ScinoPharm and Coland to Develop Oncology Drugs for China

ScinoPharm Taiwan and Coland Holdings have formed an alliance to bring generic oncology drugs to mainland China. The alliance has selected several of ScinoPharm’s APIs for development as injectible treatments. A third party will develop and man...

UPDATE 1-FDA allows generic forms of Endo Health's Opana ER painkiller

May 10 (Reuters) - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard o...

FDA Decision Opens Way to Generics of Original Opana ER

Following a decision to block new generic versions of non-abuse-deterrent oxycodone, the FDA today denied a petition from Endo Pharmaceuticals, opening the way for new generic versions of oxymorphone. Medscape Medical News

FDA Allows Generic Form of Painkiller

The FDA ruled that a new version of the powerful painkiller Opana ER doesn't thwart drug abuse significantly better than earlier versions that aren't abuse-deterrent.

FDA Rejects Endo Petition To Protect Its Opana Painkiller

The FDA rejected a citizen petition filed by Endo Pharmaceuticals which hoped to protect its Opana painkiller franchise by convincing the agency to require generics to be similarly abuse deterrent as a newer version of Opana. The decision means both...

FDA allows generic forms of Endo Health's Opana ER painkiller

(Reuters) - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain...

BRIEF-Endo Health down 2.8 percent in extended trade

NEW YORK, May 10 (Reuters) - Endo Health Solutions Inc : * Down 2.8 percent to $34 in extended trade after FDA decision on generic versions of Endo's Opana ER

Endo Health Solutions Responds to FDA's Denial of OPANA ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone

MALVERN, Pa., May 10, 2013 /PRNewswire/ --Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subs...

FDA Crushes Endo’s Hopes, Allows Original Opana Generics To Remain On Market

The agency finds reformulated Opana insufficient to deter abuse through most routes of administration and decides the original version was not removed from the market for efficacy and safety reasons; Endo had weaker in vitro and post-market data than...

Drugmaker Actavis in talks to buy Warner Chilcott

(Reuters) - Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, said on Friday that it was in early stage discussions to buy specialty pharmaceutical company Warner Chilcott Plc.

Actavis says in merger talks with Warner Chilcott

(Reuters) - Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, said on Friday that it was in early stage discussions to buy specialty pharmaceutical company Warner Chilcott Plc.

FDA Allows Opana Generics

(MedPage Today) -- The original formulation of extended-release oxymorphone (Opana ER) that lacked abuse-resistant mechanisms was not pulled from the market for safety reasons, and therefore generics based on that recipe are permissible, the FDA said...

FDA Allows Generic Form of Powerful Painkiller Opana

The FDA ruled that a new version of the powerful painkiller Opana ER doesn't thwart drug abuse significantly better than earlier versions that aren't abuse-deterrent, a decision that could make it more difficult for pharmaceutical companies to develo...

FDA denies Endo petition

FDA denied a 2012 Citizen Petition from Endo Health Solutions Inc. (NASDAQ:ENDP) asking the agency to determine that the original formulation of the company's pain drug Opana ER oxymorphone had been withdrawn due to reasons of safety. As a result, th...

Actavis, Warner Chilcott in merger talks

Shares of generics company Actavis Inc. (NYSE:ACT) and specialty pharma Warner Chilcott plc (NASDAQ:WCRX) jumped on Friday after the companies disclosed before market close they are in "early stage" discussions to merge. Actavis jumped $13.05 (12%) t...

Actavis in talks to acquire Warner Chilcott: report

(Reuters) - Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, is in early talks to acquire specialty pharmaceutical company Warner Chilcott Plc, according to a report from Bloomberg News.

FDA denies request to block generic painkiller

In a surprise move, federal health regulators have denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued can be more easily abused than its branded product.

Warner Chilcott 1Q Net Income Holds Steady

Irish drugmaker Warner Chilcott PLC said Friday its net income held steady in the first quarter despite lower sales of some of its biggest products. The company said sales of its ulcerative colitis drug Asacol fell because it stopped selling one dose...

Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal

LAVAL, Quebec, May 10, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has provided additional information related to the proposal to continue Valeant into British Columbia (the "Continuance") under the British Columbia Business Corporations Act (the "BCBCA"). The Continuance is being presented for shareholder approval at Valeant's...